Predict your next investment

Venture Capital
svhealthinvestors.com

See what CB Insights has to offer

Investments

393

Portfolio Exits

112

Funds

10

Partners & Customers

2

About SV Health Investors

SV Health Investors is a healthcare and life sciences venture capital and growth equity firm that makes investments in businesses at all stages of development and across the human life sciences sector. The firm targets early-stage opportunities in biotechnology; early-stage and revenue-stage opportunities in medical devices; and growth equity investments for later-stage businesses in healthcare services and digital health.

SV Health Investors Headquarter Location

One Boston Place 201 Washington Street, Suite 3900

Boston, Massachusetts, 02108,

United States

617-367-8100

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing SV Health Investors

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find SV Health Investors in 4 Expert Collections, including Pharma Startups.

P

Pharma Startups

5,090 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

E

Eye Health

25 items

R

Rare Diseases

25 items

G

Genomics

391 items

Investors that invest in genomics AND have made at least 10 investments (across sectors) in the past 12 months

Latest SV Health Investors News

International Biotechnology Trust : Factsheet

Aug 20, 2021

Message : Driven by strong fundamentals of the Biotech sector. Access to a broad spectrum of quoted and unquoted investments. Provides investors exposure to both growth and a competitive yield. Bottom up stock selection with diversification overlay. Scientifically and financially experienced Fund Managers with access to specialists at SV Health. Invested in some of the most innovative companies in the world. FACTSHEET - JULY 2021 Investment Manager Review In July 2021, the Trust's NAV per share returned -0.8% (GBP) while the NASDAQ Biotechnology Index (NBI) returned -0.9% (GBP). The FTSE All-Share Index returned 0.5% (GBP) and the S&P 500 Index returned 1.7% (GBP). IBT's share price returned 0.0% (GBP). Quoted Portfolio The main positive contributors to the NAV in the month were Biohaven, Horizon Therapeutics and Alnylam. Biohaven reported better than expected second quarterly margins and sales for their migraine drug Nurtec. Horizon Therapeutics announced faster than expected sales recovery and Alnylam shares moved higher on continued pipeline progress and a successful phase 3 execution for Lumasiran in Hyperoxaluria Type 1. The main detractors from the NAV in the month were PTC Therapeutics, Turning Point and Ultragenyx. PTC Therapeutics sold off heading into a catalyst rich second half of the year with data read-outs for several key projects. Turning Point shares were weak after departure of the CFO. Ultragenyx shares fell heading into their earnings report. Unquoted Portfolio During the month of July there was a net capital call made from our investment in the venture capital fund, SV Fund VI, to reflect the need to follow-on in the current portfolio of investments within this Fund. Therefore, during the current financial year to date IBT has received net distributions totalling £5.4m and the Fund has generated a net IRR of 23.4% since the date of the Trust's first investment. The remaining investments held in the unquoted portfolio within the Trust have not had any notable event since last month. Top quoted investments by NAV% Gilead NAV% by Development Stage Mid cap = USD 2 - 10BN Small cap < USD 2BN The global rollout of the vaccine bodes well for short to medium term economic recovery. Given the healthcare/biotechnology sector's relatively stable and visible earnings, combined with the accelerating pace of innovation, we are optimistic about the biotech sector's mid to long-term performance. This forecast is not a reliable indicator of future performance Performance Past performance is not a guide to future performance. Your capital is at risk. Note: All performance data are calendar year to date and are quoted net of all costs to the Company. NAV and Share Price Over Five Years Share Price (p) Fund Facts *Excludes 25 companies held by SV Fund VI FACTSHEET - JULY 2021 Lead Investment Manager Ailsa joined SV Health in 2006 and was appointed as Joint Lead Fund Manager of the Trust in March 2021. Ailsa has a BSc (Hons) in Biology from the University of Manchester. She was awarded the IMC in 2002 and the Securities Institute Diploma in 2007. Marek Poszepczynski Lead Investment Manager Marek joined SV Health in 2014 and was appointed as Joint Lead Fund Manager of the Trust in March 2021. Marek has an MSc in Biochemistry and an MSc in Business Management from the Royal Institute of Technology, Stockholm. Kate Bingham Managing Partner SV Kate joined SV Health in 1991 and represents the team of investment professionals managing the unquoted portfolio. Kate is a Managing Partner at SV Health Investors, has a first class degree in Biochemistry from Oxford University, and graduated from Harvard Business School with an MBA. Share Codes Performance Fee: See page 31 of the Annual Report 2020 Continuation Vote: At AGM in 2021; every two years Year / Interim End: 31 August / 28 February Contact Us Lucy Costa Duarte IBT-IR@svhealthinvestors.com Managing Partner SV Houman joined SV in 2016 and represents the team of investment professionals managing the unquoted portfolio. Houman is currently Head of Experimental Therapeutics at the University of Oxford and an Honorary Consultant Cardiologist, John Radcliffe Hospital, Oxford. Carl Harald Janson Senior Adviser Carl Harald joined SV Health in 2013 and continues to act as Senior Adviser to SV Health. Carl Harald qualified as a Medical Doctor and completed a PhD at the Karolinska Institutet, and is a Certified Financial Analyst from the Stockholm School of Economics. Objective The investment objective of International Biotechnology Trust plc (the "Company") is to achieve long-term capital growth by investing primarily in biotechnology and other life sciences companies that are either quoted or unquoted and possess the potential for high growth. The Company invests in companies whose shares are considered to have good prospects, with experienced management and strong potential upside through the development and/or commercialisation of a product, device or enabling technology. AIFM and Investment Manager SV Health Managers LLP was appointed Investment Manager of the Company on 1 January 2005 and Alternative Investment Fund Managers ('AIFM') on 21 July 2014. Between November 2000 and December 2004, Schroder Ventures Life Sciences Advisers (UK) Ltd, was adviser to the Investment Manager of the Company during that period, Schroder Investment Management Ltd. SV Health Managers LLP's venture capital business advises six venture capital funds with capital commitments of over USD 2bn which primarily invest amounts of between USD 1m and USD 20m in North America and Europe, but will consider innovative investments in other regions. SV Health Managers LLP manages the SV7 Impact Medicine Fund, a specialist USD 265m venture capital biotech fund and the Dementia Discovery Fund, a GBP 250m venture capital fund aiming to discover and develop breakthrough treatments for dementia. SV Health Managers LLP is Authorised and Regulated by the Financial Conduct Authority (firm reference number 409119). Further information is available on our website www.svhealthinvestors.com. This financial promotion is issued and approved by SV Health Managers LLP ("SVHM"). Notwithstanding that this document is being provided to you as a financial promotion, you should be made aware that the opportunity described in the document is not suitable for all investors. It should not be relied upon to make an investment decision; any such investment decision should be made only on the basis of the fund scheme documents and appropriate professional advice. The value of investments, and the income from them, may go down as well as up, and is not guaranteed, and investors may not get back the full amount invested. Past performance is not a guide to future performance and exchange rate changes may cause the value of overseas investments to rise or fall. Investors should bear in mind that investment in biotechnology shares can be subject to risks not normally associated with more developed markets or stocks. Investing in the biotechnology sector carries some particular risks and investment in the Company should be regarded both as long term and as carrying a high level of financial risk. In addition, there is no guarantee that the market price of shares in investment trusts will fully reflect their underlying NAV and it is not uncommon for the market price of such shares to trade at a substantial discount to their NAV. This document has been prepared and is only made available to recipients who may lawfully receive it in accordance with applicable laws, regulations and rules and binding guidance of regulators. Every effort is taken to ensure the accuracy of the data used in this document but no warranties are given. Full details of the Company, including risk warnings, are published in the Investor Disclosure Document and Key Information Document which are available on request and at www.ibtplc.com. SVHM is authorised and regulated by the Financial Conduct Authority. Attachments

SV Health Investors Investments

393 Investments

SV Health Investors has made 393 investments. Their latest investment was in Mestag Therapeutics as part of their Seed VC - II on August 8, 2021.

CBI Logo

SV Health Investors Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

8/3/2021

Seed VC - II

Mestag Therapeutics

$34M

No

Forbion Capital Partners, Google Ventures, Johnson & Johnson Innovation, and Northpond Ventures

2

7/27/2021

Series C

Artios Pharma

$153M

No

Andera Partners, Arix Bioscience, Avidity Partners, CaaS Capital, Deep Track Capital, Invus Group, IP Group, Life Sciences Partners, M Ventures, Novartis Venture Funds, Omega Fund Management, Pfizer Venture Investments, Piper Sandler, RTW Investments, Schroders, Sofinnova Partners, Soleus Capital Management, TCG Crossover, and Tetragon Financial Group

4

6/22/2021

Series A

TRexBio

$59M

Yes

Alexandria Venture Investments, Eli Lilly and Company, Johnson & Johnson Innovation, and Pfizer Venture Investments

2

5/27/2021

Series C

Subscribe to see more

$99M

Subscribe to see more

10

5/10/2021

Seed VC - III

Subscribe to see more

$99M

Subscribe to see more

10

Date

8/3/2021

7/27/2021

6/22/2021

5/27/2021

5/10/2021

Round

Seed VC - II

Series C

Series A

Series C

Seed VC - III

Company

Mestag Therapeutics

Artios Pharma

TRexBio

Subscribe to see more

Subscribe to see more

Amount

$34M

$153M

$59M

$99M

$99M

New?

No

No

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Forbion Capital Partners, Google Ventures, Johnson & Johnson Innovation, and Northpond Ventures

Andera Partners, Arix Bioscience, Avidity Partners, CaaS Capital, Deep Track Capital, Invus Group, IP Group, Life Sciences Partners, M Ventures, Novartis Venture Funds, Omega Fund Management, Pfizer Venture Investments, Piper Sandler, RTW Investments, Schroders, Sofinnova Partners, Soleus Capital Management, TCG Crossover, and Tetragon Financial Group

Alexandria Venture Investments, Eli Lilly and Company, Johnson & Johnson Innovation, and Pfizer Venture Investments

Sources

2

4

2

10

10

SV Health Investors Portfolio Exits

112 Portfolio Exits

SV Health Investors has 112 portfolio exits. Their latest portfolio exit was Avitide on September 16, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

9/16/2021

Acquired

$991

4

9/7/2021

Acquired

1

8/6/2021

Acquired

$991

2

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

Date

9/16/2021

9/7/2021

8/6/2021

00/00/0000

00/00/0000

Exit

Acquired

Acquired

Acquired

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

$991

Acquirer

Subscribe to see more

Subscribe to see more

Sources

4

1

2

10

10

SV Health Investors Acquisitions

8 Acquisitions

SV Health Investors acquired 8 companies. Their latest acquisition was Ximedica on November 05, 2014.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

11/5/2014

Loan

$3.5M

Acq - Fin

1

7/15/2011

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

8/20/2008

Subscribe to see more

$991

$99M

Subscribe to see more

10

7/22/2008

Acq - Fin

Subscribe to see more

$99M

Subscribe to see more

10

9/18/2007

Subscribe to see more

$99M

Subscribe to see more

10

Date

11/5/2014

7/15/2011

8/20/2008

7/22/2008

9/18/2007

Investment Stage

Loan

Acquired

Acq - Fin

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$991

Total Funding

$3.5M

$99M

$99M

$99M

$99M

Note

Acq - Fin

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

10

SV Health Investors Fund History

10 Fund Histories

SV Health Investors has 10 funds, including SV7 Growth Fund.

Closing Date

Fund

Fund Type

Status

Amount

Sources

11/10/2020

SV7 Growth Fund

$91.31M

3

7/20/2020

SV7 Impact Medicine Fund

$265M

2

4/6/2020

Medtech Convergence Fund

$90M

2

4/12/2017

SV Life Sciences Fund VI Strategic Partners

Subscribe to see more

$99M

10

4/11/2017

SV Life Sciences Fund VI

Subscribe to see more

$99M

10

Closing Date

11/10/2020

7/20/2020

4/6/2020

4/12/2017

4/11/2017

Fund

SV7 Growth Fund

SV7 Impact Medicine Fund

Medtech Convergence Fund

SV Life Sciences Fund VI Strategic Partners

SV Life Sciences Fund VI

Fund Type

Subscribe to see more

Subscribe to see more

Status

Amount

$91.31M

$265M

$90M

$99M

$99M

Sources

3

2

2

10

10

SV Health Investors Partners & Customers

2 Partners and customers

SV Health Investors has 2 strategic partners and customers. SV Health Investors recently partnered with Cancer Research UK on July 7, 2019.

Date

Type

Business Partner

Country

News Snippet

Sources

7/2/2019

Partner

Cancer Research UK

United Kingdom

Cancer Research UK forms partnership with SV Health Investors in life sciences investment fund to accelerate development of cancer medicines

In conjunction with the partnership , Cancer Research UK is investing at least US$ 25 million in SV Health Investors 's seventh biotech-focused venture capital fund , SV7 Impact Medicine Fund , which is expected to raise US$ 250 million .

3

7/10/2008

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

7/2/2019

7/10/2008

Type

Partner

Partner

Business Partner

Cancer Research UK

Country

United Kingdom

Subscribe to see more

News Snippet

Cancer Research UK forms partnership with SV Health Investors in life sciences investment fund to accelerate development of cancer medicines

In conjunction with the partnership , Cancer Research UK is investing at least US$ 25 million in SV Health Investors 's seventh biotech-focused venture capital fund , SV7 Impact Medicine Fund , which is expected to raise US$ 250 million .

Subscribe to see more

Subscribe to see more

Sources

3

10

SV Health Investors Team

9 Team Members

SV Health Investors has 9 team members, including current Chief Operating Officer, Managing Partner, Paul LaViolette.

Name

Work History

Title

Status

Paul LaViolette

Chief Operating Officer, Managing Partner

Current

Houman Ashrafian

Managing Partner

Current

Houman Ashrafian

Managing Partner

Current

Kate Bingham

Managing Partner

Current

Thomas Flynn

Managing Partner

Current

Name

Paul LaViolette

Houman Ashrafian

Houman Ashrafian

Kate Bingham

Thomas Flynn

Work History

Title

Chief Operating Officer, Managing Partner

Managing Partner

Managing Partner

Managing Partner

Managing Partner

Status

Current

Current

Current

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.